Neutrophilic



A Publication of the American Academy of Dermatology | Association

Neutrophilic dermatoses

By Alvaro J. Ramos, MD, FACP, and Marely Santiago-Vázquez, MD

- Heterogeneous groups of inflammatory skin disorders characterized predominantly by sterile neutrophilic infiltrates (epidermal, dermal or subcutaneous) with no evidence of infection or significant fibrinoid necrosis of vessel walls
- Cutaneous findings can vary depending on histological location of neutrophilic infiltrate ranging from:
 - Vesiculo-pustules (epidermal infiltrates)
 - Papules and plagues (dermal infiltrates)
 - o Nodules and ulcerations (dermo-hypodermal infiltrates)

Neutrophilic dermatosis	Clinical findings	Important features	Associations	Histology	Treatment			
Mainly epidermal neutrophilic infiltrates*								
Subcorneal pustular dermatosis (SPD) (Sneddon- Wilkinson disease)	Chronic, relapsing asymptomatic vesiculo-pustular dermatosis Affects mainly intetriginous areas (axilla, inframammary skin and groin) > flexor extremities and trunk Bilaterally symmetrical Recurrent crops of tiny flaccid vesicles or pustules with visible fluid levels ("hypopyon") → coalescing into annular, polycyclic or serpiginous pattern with central crusts on normal or erythematous skin	F>M; middle aged patients Hypopyon with accumulation of pustular component in dependent portion Mucosal involvement or scarring; may heal with post inflammatory hyperpigmentation Clinical and histologic features indistinguishable from SPD-type of IgA pemphigus	IgA gammopathy IgA multiple myeloma Pyoderma gangrenosum IBD	Intraepidermal (subcorneal) pustule filled with neutrophils +/- eosinophils Acantholysis may be present but not prominent Pustules sit on epidermis with no depression Negative DIF (vs. SPD-type IgA pemphigus)	Preferred: Dapsone Others: Phototherapy Systemic steroids			
Amicrobial pustulosis of the folds (APF)	Chronic, relapsing course Sudden onset of follicular and non-follicular pustular eruption, usually symmetrically distributed Crusted, eroded plaques in body folds Onychodystrophy with suppurative paronychia is a common finding Non-scarring alopecia may occur	Young female with underlying autoimmune disease Obligate dx criteria:*** Pustules involving 1 or more major body folds OR 1 minor body fold + anogenital area. Histology c/w APF Negative microbial culture from unopened pustule Minor dx criteria: Association with 1 or more autoimmune disorder (+) ANA (Titers > 1:160) Presence of 1 or more serum autoantibodies (anti-dsDNA)	Autoimmune diseases (SLE > ITP, Sjögren syndrome, autoimmune hepatitis, Hashimoto's thyroiditis, RA, IBD) (Consider screening for autoimmune disorders)	Intraepidermal (subcorneal) spongiform pustules +/- dermal infiltrate Negative DIF (Lupus band test may be (+) if underlying SLE)	Prevention of secondary infections Medium-dose systemic steroids Dapsone Colchicine Cyclosporine TNF-α inhibitors			



Alvaro J. Ramos, MD, FACP, is a dermatology resident (PGY-2) at the University of Puerto Rico School of Medicine.



Marely
SantiagoVázquez, MD,
is a dermatology
resident (PGY-2) at
the University of
Puerto Rico School
of Medicine.

p. 1 • Summer 2020 www.aad.org/DIR

By Alvaro J. Ramos, MD, FACP, and Marely Santiago-Vázquez, MD

Neutrophilic dermatosis	Clinical findings	Important features	Associations	Histology	Treatment
	Mainly (dermal +/- hypodermal ı	neutrophilic infilt	rates	
Sweet's syndrome (Acute febrile neutrophilic dermatosis)	Abrupt onset of tender, non-pruritic, well-demarcated, erythematous "juicy" papules/plaques (pseudovesiculation appearance) May develop ulcers, pustules, vesicles/bullae Usually heal without scarring Usually involves face and extremities Extracutaneous involvement: Constitutional symptoms +/- joints, ocular, lungs, bones, muscles, kidney, and liver. Neutrophilic dermatosis of the dorsal hands: variant with erythematousto-violaceous plaques +/- bullae involving dorsal hands (features of Sweet's and PG).	F> M (4:1), middle-aged (+) Pathergy Major dx criteria:** Acute onset typical lesions Histology c/w Sweet's Minor dx criteria: Fever/constitutional symptoms Leukocytosis Presence of associated conditions Rapid response to systemic steroids	Infections: Strep, Yersinia, HIV, Hep B or C, mycobacteria Malignancy: Hematologic (AML, myelodysplasia), GU, breast, colon Drugs: G-CSF, ATRA, OCPs, TMP/SMX, minocycline, furosemide, NSAIDS IBD (eg, Crohns) CTDs (eg, SLE) Pregnancy Idiopathic (~50%)	Classic Sweet's: Diffuse/nodular dermal neutrophilic infiltrate with prominent papillary edema +/- mild LCV Neutrophilic der- matosis of the dor- sal hands: Same as above, tends to have more LCV Subcutaneous Sweet's: Septal or lobular neutrophilic panniculitis (deep, erythematous, tender nodules clinically) Histiocytoid sweet's: Dermal +/- subcutaneous infiltration of neu- trophils and histio- cyte-like (immature myeloid) cells that stain (+) for MPO	May spontaneously resolve. Treat underlying cause if found. Systemic steroids Others: Dapsone Potassium iodide Colchicine
Pyoderma gangrenosum (PG)	Classic (ulcerative) PG: Papule, pustule or bullae which develops into painful, rapidly enlarging irregular ulcer with purulent base and gray-violet undermined borders that heals with atrophic, cribriform scar. Most commonly affect lower extremities. Vegetative PG: Superficial, vegetative lesions usually on trunk; least aggressive. Pyostomatitis vegetantive lesions occurring in labial/oral mucosa, or around ostomy site, respectively. Vesiculobullous PG: Superficial bullae in erythematous to violaceous background usually in face/upper extremities. Pustular PG: Grouped, small, pustular nodules.	F> M, middle-aged (40-60 y/o) (+) Pathergy Major dx criteria:** Acute, rapidly progressing painful, necrotic ulcer with irregular, violaceous undermined borders. Other causes excluded: R/o infection, vasculitis, vasculopathy, malignancy (perform sterile skin biopsy) Minor dx criteria: (+) Pathergy or cribriform scarring Classic PG histology Presence of associated conditions Rapid response to systemic steroids PAPA syndrome (mutation in PSTPIP1 encoding CD2-binding protein), PASH, PAPASH	IBD (UC > CD) Hematologic disorders (IgA monoclonal gammopathy, AML, CML, HCL, MDS, PCV) Inflammatory arthritis Vasculitis Search for associations: CBC /w peripheral smear, CXR, U/A, SPEP/ UPEP, +/-BM biopsy, colonoscopy, FOBT/0&P, ANCA	Epidermal ulceration, necrosis and/or pustules + prominent dermal neutrophilic infiltration + dermal edema +/- LCV Frequently histology is non-specific and non-diagnostic, but helpful to exclude other causes.	May spontane- ously resolve. Treat underlying cause if found. Wound care Mild cases: Ultrapotent topical or IL steroids Severe cases: Systemic steroids Others: Cyclosporine TNF-α inhibitors (infliximab) Azathioprine Methotrexate Colchicine Dapsone Potassium iodide If concurrent IBD, may benefit the most from: TNF-α inhibitors : cyclosporine > systemic steroids

p. 2 • Summer 2020 www.aad.org/DIR

By Alvaro J. Ramos, MD, FACP, and Marely Santiago-Vázquez, MD

Neutrophilic dermatosis	Clinical findings	Important features	Associations	Histology	Treatment
	Mainly der	mal +/- hypodermal neu	trophilic infiltrate	es (cont.)	l e
Necrotizing neutrophilic dermatosis	Variant of necrotizing PG and Sweet's syndrome + systemic inflammation Necrotizing, erythematous or ulcerated edematous plaques with erythematous-violaceous borders +/- satellite lesions May develop rapid progression of purpura and skin necrosis +/- purulence, pustules and edema Lower > upper extremities	Middle aged adults; M >F Fever (>38.3°C) Shock (critically ill patient; resembling sepsis without infection) Leukemoid reaction or leukocytosis Absence of infectious organisms on histopathology, microbiologic stains or tissue culture (+) history of pathergy: surgical procedure, abrasion, venipuncture	Hematologic disorders Malignant neoplasms IBD Connective tissue disease Pregnancy Medications (G-CSF)	Diffuse dermal + subcutaneous neutrophilic infiltrate May have leukocytoclasia and necrosis of fascia and muscles	Systemic steroids Unresponsiveness to antibiotic treatment may be a clue to diagnosis.
Behcet's disease	Aphthosis (oral and genital) Oral cavity/lips: Erythematous papules→ yellowish pseudomembrane → painful nonscarring ulcers with gray base and surrounding erythema. Scrotum/penis and vulva: painful ulcers with irregular margins (may mimic HSV) Other cutaneous lesions: Sterile papules +/- nonfollicular vesiculopustules, purpura, and EN-like deep erythematous, tender nodules Extracutaneous involvement: Arthritis (non-erosive) GI: cramping abdominal pain due to ulcerations within small bowel (ileocecum), colon, esophagus Others: Neurologic, vascular, cardiopulmonary or renal.	Young adult (20-35 y/o) Major dx criteria:* Recurrent oral ulcerations at least 3x/yr Minor dx criteria: Recurrent genital ulcerations Ocular involvement (leading cause of morbidity) (+) pathergy test [needle stick -> papulopustule at site of trauma w/in 1-2 days] EN, papulopustules or pseudofolliculitis; acneiform lesions (in post-adolescent not on steroids)	Middle east- ern and Mediterranean ancestry (Prevalence: Turkey > Japan > USA) Vascular thrombosis (SVC, migra- tory thrombo- phlebitis) MAGIC syndrome: Behcet's + relapsing polychondritis (antibodies against colla- gen II)	Neutrophilic angio- centric infiltrate +/- erythrocyte extravasation +/- LCV with or without thrombosis EN-like lesions: Septal or lobular neutrophilic or mixed panniculitis +/- fat necrosis	No preferred treatment Dapsone Colchicine Thalidomide IFN-α-2a Methotrexate TNF-α inhibitors (etanercept) Azathioprine Symptomatic treatment (eg, viscous lidocaine, sucralfate)

p. 3 • Summer 2020 www.aad.org/DIR

By Alvaro J. Ramos, MD, FACP, and Marely Santiago-Vázquez, MD

Neutrophilic dermatosis	Clinical findings	Important features	Associations	Histology	Treatment		
Mainly dermal +/- hypodermal neutrophilic infiltrates (cont.)							
Bowel associated dermatosis- arthritis syndrome (Bowel bypass syndrome)	Prodrome with constitutional symptoms + serum sickness-like symptoms, with: Diarrhea w/ malabsorption + Arthritis + Cutaneous lesions including: Erythematous to purpuric papules, vesiculopustules +/- tender subcutaneous nodules [EN-like]	Lesions favor proximal extremities and trunk Progress within 48 hours May last 2-4 weeks Frequent recurrences	Gastric resection Jejunoileal bypass Blind loops of bowel Biliopancreatic diversion IBD, diverticu- litis, PUD	Dermal perivascular nodular neutrophilic infiltrates +nuclear dust + dermal edema EN-like lesions: Septal or lobular neutrophilic panniculitis	Surgical correction of blind loop or bowel bypass revision-> curative Antibiotics (eg, tetracyclines) + systemic immunomodu- lating agents -> symptomatic improvement		
Neutrophilic eccrine hidradenitis	Erythematous-to- purpuric painful mac- ules, papules and/ or plaques on face, extremities and trunk. May develop pustules Lesions heal without scarring	Dermatosis usually occur 8-10 days after drug exposure Fever and neutropenia may occur	Chemotherapy (cytarabine, anthracyclines, methotrexate, bleomycin) Other drugs: G-CSF, acet-aminophen, carbamazepine Cancer: Leukemia (AML), testicular, breast, bone Infections: HIV, Staph, nocardia, serratia, enterobacter	Neutrophilic infiltrate around eccrine unit +/- necrosis and eccrine squamous syringometaplasia	Treat underlying infection/stop offending agent Usually spontaneous resolution. Systemic steroids Dapsone		
Erythema elevatum diutinum (EED)	Violaceous, erythematous or red brown papules, smooth nodules or plaques Extensor extremities (elbows, knees) in a symmetric distribution +/- Arthralgias	Middle-aged adults Lesions may increase in number and size with time	Infections (strep, syphilis, hepatitis, HIV) Hematologic disorders: (Lymphoma, multiple myeloma, IgA monoclonal gammopathy) IBD	Dermal neutro- philic infiltrate +/- eosinophils + LCV Older lesions may have fibrosis	Dapsone Systemic steroids		
Neutrophilic panniculitis (NP)	Painful, inflammatory subcutaneous nodules or plaques mainly locat- ed on lower extremities. May develop fever, arthralgias, and fatigue	F>M; Middle aged adults	Hematologic malignancies, MDS, mono- clonal gam- mopathies IBD, RA Drugs (eg, BRAF and tyrosine kinase inhibitors, G-CSF)	Lobular neutrophil- ic panniculitis+/- dermal infiltrate No vasculitis	Systemic steroids		

p. 4 • Summer 2020 www.aad.org/DIR

By Alvaro J. Ramos, MD, FACP, and Marely Santiago-Vázquez, MD

Neutrophilic dermatosis	Clinical findings	Important features	Associations	Histology	Treatment			
	Mainly dermal +/- hypodermal neutrophilic infiltrates (cont.)							
Rheumatoid neutrophilic dermatitis (RND)	Asymptomatic papules, plaques, nodules, urticarial plaques or palpable purpura Extensor extremities > trunk, shoulder, neck in symmetric distribution	Middle aged female with severe seroposi- tive RA	Rheumatoid arthritis	Dense neutro- philic infiltrate, plasma cells and macrophages +/-microabscess in papillary dermis (similar to dermati- tis herpetiformis) DIF: negative	May resolve spontaneously or with treat- ment of underly- ing RA High potency topical steroids Dapsone Systemic steroids			

^{*}Also includes: pustular psoriasis, acute generalized exanthematous pustulosis, IgA pemphigus, infantile acropustulosis and transient neonatal pustulosis

References:

- 1. Alikhan A, Hocker T. Review of Dermatology, 1st ed. Elsevier. 2016.
- Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018 Dec;79(6):1009-1022
- 3. Bolognia JA, Schaffer JV, Cerroni L. Dermatology, 4th ed. Elsevier. 2018.
- 4. Filosa a, Filosa G. Neutrophilic dermatoses: a broad spectrum of disease. G ital dermatol Venereol 2018;153:265-72. doi: 10.23736/S0392-0488.18.05841-8.
- 5. Maverakis E, Ma C, Shinkai K, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018 Feb 14;. PubMed ID: 29450466
- Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018 Dec;79(6):987-1006. PubMed ID: 29653210
- 7. Partridge ACR, Bai JW, Rosen CF, Walsh SR, Gulliver WP, Fleming P. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol. 2018;179(2):290-295.

Abbreviations:

F: Female; M: Male; IBD: Inflammatory bowel disease; DIF: Direct immunofluorescence, Dx: Diagnostic; c/w: Consistent with; ANA: antinuclear antibodies; anti-dsDNA: anti-double stranded DNA; SLE: Systemic lupus erythematosus; PAPA: Pyogenic Arthritis, Pyoderma Gangrenosum, Acne Conglobata; PASH: Pyoderma gangrenosum, Acne, Suppurative Hidradenitis; PAPASH: Pyogenic arthritis, Pyoderma gangrenosum, Acne, Suppurative Hidradenitis; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; HCL: Hairy cell leukemia; MDS: Myelodysplastic syndrome; RA: Rheumatoid arthritis; PCV: Polycythemia vera; CBC: Complete blood count; CXR: Chest x-ray; U/A: Urine analysis; SPEP/UPEP: Serum protein electrophoresis/Urine protein electrophoresis; BM: Bone marrow; FOBT/0&P: Fecal occult blood test/Ova and parasites; ANCA: anti-neutrophil cytoplasmic antibodies; G-CSF: Granulocyte-colony stimulating factor; LCV: Leukocytoclastic vasculitis

p. 5 • Summer 2020 www.aad.org/DIR

^{**}Both major and two minor proposed criteria are needed for the diagnosis.

^{***}Diagnosis established if proposed obligate criteria and at least 1 minor criteria present.